Acetylcysteine

Generic Name: Acetylcysteine

Brand Names: Acetadote

Drug Type: Small Molecule

Chemical Formula: C_₅H_₉NO_₃S

CAS Number: 616-91-1

Unique Ingredient Identifier: WYQ7N0BPYC

Background: Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.

Acetylcysteine was granted FDA approval on 14 September 1963.

Indication: Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.

Associated Conditions: Acetaminophen Overdose, Chronic Rhinitis, Corneal Diseases, Corneal ulceration, Crusting Rhinitis, Keratopathy, Rhinitis, Sinusitis, Vasomotor Rhinitis, Acute Rhinitis, Subacute Rhinitis

Associated Therapies: Airway secretion clearance therapy

Clinical Trials

Effect of N-acetylcysteine on Renal Functioning of Chronic Kidney Diseases(CKD) Patients After General Anesthesia

Phase 1

Conditions: Chronic Kidney Diseases
General Anesthesia

Interventions: Drug: N-acetylcysteine
Drug: Siran (N-acetylcysteine)

First Posted Date: 2010-12-01

Last Posted Date: 2010-12-01

Lead Sponsor: Assaf-Harofeh Medical Center

Registration Number: NCT01251029

Locations: 🇮🇱
Assaf Harofeh Medical Center, Zerifin, Israel

Induced Changes in Ventilatory Responsiveness and Altitude Exposure

Phase 4

Terminated

Conditions: Abnormal Blood Oxygen Pressure
Effects of High Altitude
Inadequate or Impaired Breathing Pattern or Ventilation
Hypoxia

Interventions: Drug: NAC
Drug: Placebo

First Posted Date: 2010-11-16

Last Posted Date: 2020-04-30

Lead Sponsor: United States Army Research Institute of Environmental Medicine

Target Recruit Count: 21

Registration Number: NCT01241513

Locations: 🇺🇸
USARIEM, Natick, Massachusetts, United States

Effect of N-acetylcysteine (NAC) on Hydrogen Sulfide (H2S) in Chronic Kidney Disease (CKD)

Phase 3

Completed

Conditions: Chronic Kidney Disease
Chronic Kidney Failure
End Stage Kidney Disease
End Stage Renal Disease

Interventions: Drug: N-acetylcysteine

First Posted Date: 2010-11-02

Last Posted Date: 2012-10-26

Lead Sponsor: A.C. Abrahams

Target Recruit Count: 28

Registration Number: NCT01232257

Locations: 🇳🇱
UMC Utrecht, Utrecht, Netherlands

Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru

Phase 1

Completed

Conditions: Mountain Sickness
Erythrocytosis

Interventions: Drug: Placebo pills
Drug: N-acetylcysteine
Drug: Acetazolamide

First Posted Date: 2010-08-23

Last Posted Date: 2015-05-15

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 85

Registration Number: NCT01187108

Locations: 🇵🇪
Chronic mountain sickness clinic, Cerro de Pasco, Pasco, Peru

N-acetylcysteine (NAC) for Pediatric Obsessive-Compulsive Disorder

Phase 2

Completed

Conditions: Obsessive-Compulsive Disorder

Interventions: Other: Placebo
Drug: N-Acetylcysteine

First Posted Date: 2010-07-29

Last Posted Date: 2019-09-06

Lead Sponsor: Yale University

Target Recruit Count: 11

Registration Number: NCT01172275

Locations: 🇺🇸
Yale Child Study Center, New Haven, Connecticut, United States

Prevention of Contrast-induced Nephropathy in Patients With Acute Myocardial Infarction

Not Applicable

Completed

Conditions: Contrast Induced Nephropathy

Interventions: Other: Hydration
Drug: Combined Acetylcystein and Sodium Bicarbonate
Drug: Sodium bicarbonate
Drug: Acetylcysteine

First Posted Date: 2010-07-12

Last Posted Date: 2013-03-22

Lead Sponsor: Odense University Hospital

Target Recruit Count: 720

Registration Number: NCT01160627

Locations: 🇩🇰
Odense University Hospital, Odense, Denmark

Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine

Not Applicable

Conditions: Visceral Leishmaniasis
Immune Response
Treatment

Interventions: Drug: Pentavalent antimonial
Drug: N-acetylcysteine

First Posted Date: 2010-06-08

Last Posted Date: 2010-06-08

Lead Sponsor: Hospital Universitário Professor Edgard Santos

Target Recruit Count: 40

Registration Number: NCT01138956

Locations: 🇧🇷
University Hospital, Aracaju, Sergipe, Brazil

N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer

Phase 1

Withdrawn

Conditions: Primary Peritoneal Carcinoma
Ovarian Carcinoma, Stage 3 or 4
Epithelial Ovarian Carcinoma

Interventions: Drug: Paclitaxel
Drug: N-acetylcysteine
Drug: Cisplatin

First Posted Date: 2010-06-07

Last Posted Date: 2017-04-21

Lead Sponsor: OHSU Knight Cancer Institute

Registration Number: NCT01138137

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Prevention of Drug Induced Ototoxicity in Peritoneal Dialysis Patients by N-Acetylcysteine

Phase 2

Completed

Conditions: Drug-induced Ototoxicity in Peritoneal Dialysis Patients

Interventions: Drug: N-acetylcysteine

First Posted Date: 2010-05-27

Last Posted Date: 2010-05-27

Lead Sponsor: TC Erciyes University

Target Recruit Count: 60

Registration Number: NCT01131468

Locations: 🇹🇷
Erciyes University School of Medicine Department of Nephrology, Kayseri, Turkey

Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection

Phase 3

Terminated

Conditions: Acetaminophen Overdose

Interventions: Drug: Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free)
Drug: Acetadote

First Posted Date: 2010-05-07

Last Posted Date: 2014-08-04

Lead Sponsor: Cumberland Pharmaceuticals

Target Recruit Count: 17

Registration Number: NCT01118663

Locations: 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸
East Carolina University Medical Center, Greenville, North Carolina, United States
🇺🇸
Toledo Hospital, Toledo, Ohio, United States

and more 11 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy